Homology Medicines, Inc. (FIXX): Price and Financial Metrics
FIXX Price/Volume Stats
| Current price | $16.82 | 52-week high | $17.51 |
| Prev. close | $0.93 | 52-week low | $0.46 |
| Day low | $16.20 | Volume | 22,300 |
| Day high | $17.51 | Avg. volume | 390,307 |
| 50-day MA | $0.78 | Dividend yield | N/A |
| 200-day MA | $0.91 | Market Cap | 978.08M |
FIXX Stock Price Chart Interactive Chart >
Homology Medicines, Inc. (FIXX) Company Bio
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.
Latest FIXX News From Around the Web
Below are the latest news stories about HOMOLOGY MEDICINES INC that investors may wish to consider to help them evaluate FIXX as an investment opportunity.
Homology enters reverse merger with Q32 BioThe deal, which will result in a combined company operating under Q32's name, comes months after Homology laid off much of its staff. |
Q32 Bio and Homology Medicines Announce Merger Agreement--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders-- --Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and TSLP-mediated signaling, and remains on-track to report multiple |
Homology Medicines Reports Third Quarter 2023 Financial Results- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates. Homology recently shared a summary of safety and efficacy data on the first dose cohort of the pheEDIT clinical trial evaluating the Company’s HMI-103 gene editing candidate for |
Can Homology Medicines (NASDAQ:FIXX) Afford To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights- Reported Encouraging Initial Data from First Cohort of Phase 1 Trial Evaluating Gene Editing Candidate HMI-103 in Adults with PKU - - Evaluating Strategic Options for the Company and Pipeline of Genetic Medicines, including HMI-103 - BEDFORD, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates. “We recently shared the encouraging initial data from the |
FIXX Price Returns
| 1-mo | N/A |
| 3-mo | 33.11% |
| 6-mo | -8.39% |
| 1-year | -6.56% |
| 3-year | -85.07% |
| 5-year | -95.85% |
| YTD | 53.69% |
| 2023 | -51.75% |
| 2022 | -65.38% |
| 2021 | -67.76% |
| 2020 | -45.46% |
| 2019 | -7.42% |
Continue Researching FIXX
Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...